Literature DB >> 10774585

Antiretroviral therapy: state of the HAART.

S Vella1, L Palmisano.   

Abstract

Mesh：

Substances：

Year:  2000        PMID： 10774585     DOI： 10.1016/s0166-3542(99)00068-6

Source DB:  PubMed          Journal:  Antiviral Res        ISSN： 0166-3542            Impact factor:   5.970


× No keyword cloud information.
  19 in total

1.  Optimization of 2,4-diarylanilines as non-nucleoside HIV-1 reverse transcriptase inhibitors.

Authors:  Lian-Qi Sun; Bingjie Qin; Li Huang; Keduo Qian; Chin-Ho Chen; Kuo-Hsiung Lee; Lan Xie
Journal:  Bioorg Med Chem Lett       Date:  2012-02-24       Impact factor: 2.823

2.  Prevalence of protease and reverse transcriptase drug resistance mutations over time in drug-naïve human immunodeficiency virus type 1-positive individuals in Rio de Janeiro, Brazil.

Authors:  Ana T Dumans; Marcelo A Soares; Danuta Pieniazek; Marcia L Kalish; Veronique De Vroey; Kurt Hertogs; Amilcar Tanuri
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

3.  In vitro hypersusceptibility of human immunodeficiency virus type 1 subtype C protease to lopinavir.

Authors:  Luis M F Gonzalez; Rodrigo M Brindeiro; Michelle Tarin; Alexandre Calazans; Marcelo A Soares; Sharon Cassol; Amilcar Tanuri
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

4.  Drug resistance mutations in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase differentially affect the phosphorolysis-dependent primer unblocking activity in the presence of stavudine and zidovudine and its inhibition by efavirenz.

Authors:  Emmanuele Crespan; Giada A Locatelli; Reynel Cancio; Ulrich Hübscher; Silvio Spadari; Giovanni Maga
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

5.  Towards discovering dual functional inhibitors against both wild type and K103N mutant HIV-1 reverse transcriptases: molecular docking and QSAR studies on 4,1-benzoxazepinone analogues.

Authors:  Zhenshan Zhang; Mingyue Zheng; Li Du; Jianhua Shen; Xiaomin Luo; Weiliang Zhu; Hualiang Jiang
Journal:  J Comput Aided Mol Des       Date:  2006-08-08       Impact factor: 3.686

6.  Optimization of the antiviral potency and lipophilicity of halogenated 2,6-diarylpyridinamines as a novel class of HIV-1 NNRTIS.

Authors:  Zhi-Yuan Wu; Na Liu; Bingjie Qin; Li Huang; Fei Yu; Keduo Qian; Susan L Morris-Natschke; Shibo Jiang; Chin Ho Chen; Kuo-Hsiung Lee; Lan Xie
Journal:  ChemMedChem       Date:  2014-06-04       Impact factor: 3.466

7.  High potency of indolyl aryl sulfone nonnucleoside inhibitors towards drug-resistant human immunodeficiency virus type 1 reverse transcriptase mutants is due to selective targeting of different mechanistic forms of the enzyme.

Authors:  Reynel Cancio; Romano Silvestri; Rino Ragno; Marino Artico; Gabriella De Martino; Giuseppe La Regina; Emmanuele Crespan; Samantha Zanoli; Ulrich Hübscher; Silvio Spadari; Giovanni Maga
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

8.  Domestic cat model for predicting human nucleoside analogue pharmacokinetics in blood and seminal plasma.

Authors:  H L Jordan; A S Pereira; M S Cohen; A D Kashuba
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

9.  Effects of drug resistance mutations L100I and V106A on the binding of pyrrolobenzoxazepinone nonnucleoside inhibitors to the human immunodeficiency virus type 1 reverse transcriptase catalytic complex.

Authors:  Giada A Locatelli; Giuseppe Campiani; Reynel Cancio; Elena Morelli; Anna Ramunno; Sandra Gemma; Ulrich Hübscher; Silvio Spadari; Giovanni Maga
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

10.  Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent.

Authors:  Roger G Ptak; Philippe A Gallay; Dirk Jochmans; Andrew P Halestrap; Urs T Ruegg; Luke A Pallansch; Michael D Bobardt; Marie-Pierre de Béthune; Johan Neyts; Erik De Clercq; Jean-Maurice Dumont; Pietro Scalfaro; Kamel Besseghir; Roland M Wenger; Brigitte Rosenwirth
Journal:  Antimicrob Agents Chemother       Date:  2008-01-22       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.